STEREOTACTIC SYSTEMS MARKET ANALYSIS

Market Challenges And Opportunities

Stereotactic Systems Market Drivers

Rapid innovation in minimally invasive surgery techniques is one of the major factors, which is expected to boost growth of the stereotactic systems market. For instance, in November 2018, Monteris Medical, published the favorable clinical data for its NeuroBlate Laser Ablation after Stereotactic Radiosurgery (LAASR) for patients with brain metastasis in the Journal of Neurosurgery. The NeuroBlate System is a minimally invasive, robotically controlled laser thermotherapy that uses MRI-guided laser light to ablate unwanted tissue in the brain where the lesion originates. Monteris is exclusively focused on advancing both LITT technology and clinical research to serve the unmet needs of neurosurgeons and their patients.

Furthermore, in December 2017, the U.S. Food and Drug Administration approved GammaPod, new system of Xcision Medical Systems, LLC. GammaPod is a noninvasive stereotactic radiotherapy system intended for treating cancer in breast tissue.

Moreover, in March 2018, Sunway Medical Centre (SunMed), Malaysia’s multi-disciplinary Medical Centre, introduced Leksell Gamma Knife Icon (an advanced radiation machine, which was manufactured by Elekta AB). It is used for the treatment of various neurological disorders and brain conditions that require open brain surgery.

Stereotactic Systems Market Restraints

However, some risk factors associated with the use of stereotactic systems may hamper growth     of the market. For instance, in November 2018, the clinical trial for stereotactic body radiation therapy, sponsored by Case Comprehensive Cancer Center, was terminated due to major side effects while treating patients with advanced head and neck cancer.